Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Statistics
Share Statistics
Vertex Pharmaceuticals has 256.79M shares outstanding. The number of shares has increased by -0.3% in one year.
| Shares Outstanding | 256.79M |
| Shares Change (YoY) | -0.3% |
| Shares Change (QoQ) | -0.22% |
| Owned by Institutions (%) | 89.6% |
| Shares Floating | 255.90M |
| Failed to Deliver (FTD) Shares | 219 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.39M, so 1.71% of the outstanding shares have been sold short.
| Short Interest | 4.39M |
| Short % of Shares Out | 1.71% |
| Short % of Float | 1.71% |
| Short Ratio (days to cover) | 2.1 |
Valuation Ratios
The PE ratio is -193.61 and the forward PE ratio is 23.43. Vertex Pharmaceuticals's PEG ratio is 1.69.
| PE Ratio | -193.61 |
| Forward PE | 23.43 |
| PS Ratio | 9.41 |
| Forward PS | 7.2 |
| PB Ratio | 6.32 |
| P/FCF Ratio | -131.21 |
| PEG Ratio | 1.69 |
Enterprise Valuation
Vertex Pharmaceuticals has an Enterprise Value (EV) of 95.29B.
| EV / Earnings | -177.92 |
| EV / Sales | 8.65 |
| EV / EBITDA | 195.95 |
| EV / EBIT | -409.15 |
| EV / FCF | -120.58 |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.69 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.11 |
| Total Debt / Capitalization | 9.63 |
| Cash Flow / Debt | -0.28 |
| Interest Coverage | -7.61 |
Financial Efficiency
Return on equity (ROE) is -0.03% and return on capital (ROIC) is 2.76%.
| Return on Equity (ROE) | -0.03% |
| Return on Assets (ROA) | -0.02% |
| Return on Capital (ROIC) | 2.76% |
| Revenue Per Employee | 1.81M |
| Profits Per Employee | -87.80K |
| Employee Count | 6.10K |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.27 |
Taxes
| Income Tax | 784.10M |
| Effective Tax Rate | 3.16 |
Stock Price Statistics
The stock price has increased by 14.48% in the last 52 weeks. The beta is 0.41, so Vertex Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | 14.48% |
| 50-Day Moving Average | 439.91 |
| 200-Day Moving Average | 463.29 |
| Relative Strength Index (RSI) | 60.58 |
| Average Volume (20 Days) | 1.63M |
Income Statement
In the last 12 months, Vertex Pharmaceuticals had revenue of 11.02B and earned -535.60M in profits. Earnings per share was -2.08.
| Revenue | 11.02B |
| Gross Profit | 9.49B |
| Operating Income | -232.90M |
| Net Income | -535.60M |
| EBITDA | 486.30M |
| EBIT | -232.90M |
| Earnings Per Share (EPS) | -2.08 |
Balance Sheet
The company has 4.57B in cash and 1.75B in debt, giving a net cash position of 2.82B.
| Cash & Cash Equivalents | 4.57B |
| Total Debt | 1.75B |
| Net Cash | 2.82B |
| Retained Earnings | 9.61B |
| Total Assets | 22.53B |
| Working Capital | 6.03B |
Cash Flow
In the last 12 months, operating cash flow was -492.60M and capital expenditures -297.70M, giving a free cash flow of -790.30M.
| Operating Cash Flow | -492.60M |
| Capital Expenditures | -297.70M |
| Free Cash Flow | -790.30M |
| FCF Per Share | -3.07 |
Margins
Gross margin is 86.11%, with operating and profit margins of -2.11% and -4.86%.
| Gross Margin | 86.11% |
| Operating Margin | -2.11% |
| Pretax Margin | 2.25% |
| Profit Margin | -4.86% |
| EBITDA Margin | 4.41% |
| EBIT Margin | -2.11% |
| FCF Margin | -7.17% |
Dividends & Yields
VRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.43% |
| FCF Yield | -0.64% |
Analyst Forecast
The average price target for VRTX is $520, which is 8.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $520 |
| Price Target Difference | 8.2% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
Stock Splits
The last stock split was on Aug 24, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 24, 2000 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 13.32 |
| Piotroski F-Score | 5 |